Brief: Immuron Plans Phase 2 Trial For Imm-529 Following FDA Review
Immuron Ltd IMC.AX :
* IMMURON PLANS PHASE 2 TRIAL FOR IMM-529 FOLLOWING FDA
REVIEW
* IMMURON LTD - INVESTIGATIONAL NEW DRUG (IND) APPLICATION
FOR
IMM-529 PLANNED FOR 1H 2025
* IMMURON - COMPLETES PRE-IND MEETING WITH FDA ON
DEVELOPMENT OF
IMM-529 AS PRODUCT TO SPECIFICALLY PREVENT OR TREAT
CLOSTRIDIOIDES DIFFICILE INFECTION
Source text for Eikon: ID:n0001213900-24-075787
Further company coverage: IMC.AX
Recent news on Immuron
See all newsBrief: Immuron Engages LifeSci Capital as its Exclusive Financial Advisor to Explore Strategic Initiatives
Australia's Immuron hits near 1.5-month high on distribution deal in US
Brief: Immuron Executes Exclusive Distribution Agreement For Proibs In The United States
Brief: Immuron Reports FY26 Preliminary Results
Brief: Immuron Posts FY Revenue From Ordinary Activities Of A$7.71 Million